Recruiting

Deployment o the Multidisciplinary Prospective Cohort Imminent

ClinicalTrials.gov IDNCT04334031

PhaseNA

Enrollment2200

SponsorUniversity Hospital, Lille

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Chronic Inflammatory Disease, Angioedema, Severe Asthma, Lupus, Atopic Dermatitis, Psoriatic Arthritis, Multiple Sclerosis, Systemic Sclerosis, Behçet Disease

About this study

Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions. Beyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as "targeted therapies". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment. These similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.

Interventions

Genetic: Biobanking with genetic analysis — Patients included in the IMMINeNT cohort will be collected 7 blood samples for the research project at each revaluation visit. For patients who accepted, genetic analysis (DNA analysis) will be done on a part of those samples.
Other: SF-12 questionnaire — Patients included in the IMMINeNT cohort will be asked to complete SF-12 quality of life questionnaire.

Primary outcomes

Change of SLEDAI for lupus (once a year for 10 years)
Change of Medsger score (once a year for 10 years)
Change of EDSS for multiple sclerosis (once a year for 10 years)
Change of BASDAI for psoriatic arthristis (once a year for 10 years)
Change of Longhurst criteria for hereditary angioedema (once a year for 10 years)
Change of number of flares for atopic dermatitis (once a year for 10 years)
Change of number of exacerbations for severe asthma (once a year for 10 years)
Change of 12-Item Short-Form Health Survey (SF-12) - quality of life scale (once a year for 10 years)

Eligibility information

Inclusion Criteria: * Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology) * Social insured * Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures. Exclusion Criteria: * Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system. * Pregnant or breastfeeding woman * Persons deprived of liberty * Protected minors or adults * Persons who have refused or are incapable of giving informed consent * Persons in Emergency Situations

Study locations

Hop Claude Huriez Chu Lille, Lille, 59037 France

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.